CA
SMMT icon

Cliff Asness’s Summit Therapeutics SMMT Stock Holding History

Cliff Asness’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.9M Buy
542,178
+98,421
+22% +$1.75M ﹤0.01% 1719
2026
Q1 		$8.11M Buy
443,757
+85,887
+24% +$1.39M ﹤0.01% 1448
2025
Q4 		$6.19M Buy
357,870
+170,386
+91% +$3.21M ﹤0.01% 1447
2025
Q3 		$3.87M Buy
187,484
+165,172
+740% +$4.01M ﹤0.01% 1600
2025
Q2 		$475K Sell
22,312
-43,311
-66% -$988K ﹤0.01% 2639
2025
Q1 		$1.27M Buy
65,623
+3,134
+5% +$62.9K ﹤0.01% 1873
2024
Q4 		$1.12M Sell
62,489
-6,029
-9% -$117K ﹤0.01% 1831
2024
Q3 		$1.5M Buy
68,518
+6,404
+10% +$89.6K ﹤0.01% 1636
2024
Q2 		$484K Buy
+62,114
New +$335K ﹤0.01% 2070
2023
Q4 		– Sell
-19,225
Closed -$36K – 2437
2023
Q3 		$36K Buy
+19,225
New +$36.7K ﹤0.01% 2296

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Cliff Asness's SMMT Position: Q2 2026 in Review

Cliff Asness increased its Summit Therapeutics (SMMT) stake by 22% in Q2 2026, buying an estimated $1.75M and bringing the position to 542,178 shares worth $7.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Cliff Asness first reported a position in SMMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $8.11M in Q1 2026. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Cliff Asness held 542,178 shares of Summit Therapeutics worth $7.9M as of Q2 2026.
  • Cliff Asness bought 98,421 Summit Therapeutics shares in Q2 2026, an estimated $1.75M.
  • Summit Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1719 holding.
  • Cliff Asness first reported a position in Summit Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • Cliff Asness's Summit Therapeutics position peaked at $8.11M in Q1 2026.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.